Paul Castella

Paul Castella brings to StemBioSys® an impressive track record of highly successful development and commercialization of life science startup companies.

In two years as co-founder, president and CFO, he led CardioSpectra to a $63-million acquisition by Volcano Corp. In addition, he has co-founded, managed and financed several other companies including Xenotope Diagnostics, which licensed its technology to Genzyme, and ViroXis, which has received funding from the State of Texas and is conducting an investigational new drug phase II study.

He co-founded Targeted Technology Fund I in 2009, immediately attracting a long list of life science business leaders to the fund’s focus on investment in promising startup enterprises.

The holder of 20 issued or pending patents, Dr. Castella serves as a director or advisor with numerous biotechnology and pharmaceutical companies. His skills in the evaluation, financing, licensing, formation and operation of life science companies continues to be in high demand.

Dr. Castella holds a Ph.D. in cell biology and genetics from Cornell University Medical College and an M.B.A. from the University of Texas.